COVID-19 Vaccine Global Intellectual Property Policy

https://policybase.cma.ca/link/policy14458

POLICY TYPE: Policy document
DATE: 2021-10-22
TOPICS: Physician practice, compensation, forms

COVID-19 Vaccine Global Intellectual Property Policy

Policy position recommendation

1. The CMA recommends the Government of Canada (or the provincial or territorial governments, as applicable) support the development and approval of COVID-19 vaccines through temporary modifications to the intellectual property rights of current vaccines.

The following policies are suggested by the CMA:

1. Novavax vaccine, including both meningitis B and tetanus toxoid requirements, and the COVID-19 vaccine dose in children (12 to 15 years old), requires the approval of the Canadianwindows under section 4(7) of the Patents Act.

2. New COVID-19 vaccines that are approved after December 1, 2021, require the approval of the Canadianwindows under section 4(7) of the Patents Act.

3. It is recommended that the Government of Canada support the development and approval of COVID-19 vaccines through temporary modifications to the intellectual property rights of current vaccines.

4. The following policies are suggested by the CMA:

a. The Government of Canada should support the development and approval of COVID-19 vaccines through temporary modifications to the intellectual property rights of current vaccines.

b. The Government of Canada should support the development and approval of COVID-19 vaccines through temporary modifications to the intellectual property rights of current vaccines.

The CMA recommends that the Government of Canada support the development and approval of COVID-19 vaccines through temporary modifications to the intellectual property rights of current vaccines.

CMA Policybase - Canadian Medical Association